ADMA SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds ADMA Biologics Investors of Securities Class Action Lawsuit Deadline on August 10, 2026

Impact · against what's priced in

ADMA Biologics faces severe valuation risks following allegations of systemic revenue manipulation via channel stuffing and undisclosed related party transactions. This news suggests that the 20% growth reported in 2025 was artificial and that actual growth was negative 3%, fundamentally undermining the company's reported financial health.

ADMA−0.80

No priced-in read yet